Table 4.
T-cell subset frequencies in new-onset T1DM, LADA, and T2DM patients and NGT subjects.
| NGT (n=80) | T2DM (n=39) | LADA (n=16) | T1DM (n=35) | |
|---|---|---|---|---|
| CD4+ T | 41.60 (35.80, 46.90) | 44.80 (39.20, 49.90) | 46.75 (40.20, 55.60) | 42.75 (36.75, 50.50) |
| IFN-γ+CD4+ T | 15.30 (10.9, 22.00) | 16.70 (9.97, 20.80) | 11.70 (9.48, 22.00) | 10.90 (6.03, 16.50) |
| Th2 | 1.94 (1.29, 2.65) | 2.16 (2.05, 4.05) | 1.62 (0.87, 2.57) | 2.23 (1.51, 2.90) |
| Th17 | 1.06 (0.67, 1.56) | 1.45 (0.94, 2.57) | 1.07 (0.78, 1.59) | 0.89 (0.59, 1.07) |
| IFN-γ+CD8+ T | 48.35 (31.2, 61.75) | 38.50 (21.90, 50.50) | 27.80 (11.15,45.22)** | 25.00 (15.35, 31.80)** |
| Treg | 2.52 (1.60, 3.42) | 3.06 (2.20, 4.05) | 2.75 (1.95, 4.10) | 2.40 (1.77, 3.20) |
| CD4+ Naïve T | 40.18(31.22, 48.57) | 39.41 (27.39, 45.89) | 43.13 (24.71, 55.68) | 52.27 (39.80, 58.86) |
| CD4+ Tcm | 9.38 (6.31, 16.37) | 18.63 (8.07, 26.27) | 13.14 (7.19,20.85) | 12.72 (9.64, 21.10) |
| CD4+ Teff | 3.45 (1.38, 6.28) | 2.22 (0.80. 5.09) | 2.31 (0.77, 4.03) | 1.53 (1.04, 3.71) |
| CD4+ Tem | 4.91 (2.82, 9.52) | 12.99 (9.11,21.07)*** | 6.48 (4.45, 10.85)††† | 6.02 (4.58, 7.99)††† |
| CD8+ T | 20.70 (15.40, 24.80) | 21.20 (17.90, 26.70) | 19.25 (15.97, 27.65) | 23.65 (15.75, 29.05) |
| CD8+ Naïve T | 31.87 (20.35, 46.83) | 22.38 (13.60, 39.44) | 48.77 (28.95, 64.55)††† | 48.70 (37.73, 58.00)† |
| CD8+ Tcm | 3.03 (2.02, 4.11) | 4.54 (2.18, 7.07) | 4.04 (1.81, 6.62) | 1.89 (1.31, 3.97) |
| CD8+ Teff | 8.17 (4.65, 16.75) | 13.90 (9.50, 21.18) | 5.24 (3.42, 8.73) | 7.27 (3.76, 13.67) |
| CD8+ Tem | 9.21 (6.35, 15.47) | 20.46 (12.41,32.82)*** | 10.00 (3.56,18.56)††† | 8.84 (6.15, 11.80)††† |
Compared with NGT **p<0.01,*** p<0.001. Compared with T2D †p<0.05, †††p<0.001. Data are expressed as the median values (25th-75th percentiles) and compared by the Kruskal-Wallis test. New-onset: disease duration less than one year. LADA, patients with latent autoimmune diabetes in adults; NGT, normal glucose tolerance subjects; T1D, type 1 diabetic subjects; T2D, type 2 diabetic subjects.